{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-009383","form_type":"8-K","ticker":"NAGE","cik":"0001386570","company_name":"Niagen Bioscience, Inc.","filed_at":"2024-03-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.020035+00:00","generated_at":"2026-06-05T02:29:58.481613+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"ChromaDex posts Q4 net income of $0.1M; FY2023 revenue up 16% to $83.6M","bullets":["Q4 net sales $21.2M (+1% YoY); Tru Niagen sales $17.6M (+9% YoY).","Q4 gross margin 61.0% (up 380 bps); net income $0.1M vs loss of $1.4M prior year.","Full-year net loss improved $11.6M to $4.9M; positive Adjusted EBITDA of $1.9M.","Cash $27.3M, no debt; positive operating cash flow for fourth consecutive quarter.","Exceeded FY2023 outlook for gross margin and G&A; expects accelerated growth in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-009383","json":"https://secwatch.observer/filing/0001628280-24-009383.json","markdown":"https://secwatch.observer/filing/0001628280-24-009383.md","text":"https://secwatch.observer/filing/0001628280-24-009383.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1386570/000162828024009383/0001628280-24-009383-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1386570/000162828024009383/cdxc-20240306.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T02:29:58.481613+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a0ba39853b260dceaa36249e0d5a5572d3173abf","claim":"Niagen Bioscience, Inc. reported Fourth Quarter 2023 results: revenue $21.2 million, net income net income of $0.1 million, EPS $0.00 earnings per share.","evidence_excerpt":"Fourth quarter net sales of $21.2 million, gross margin of 61.0%, and net income of $0.1 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1386570/000162828024009383/0001628280-24-009383-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Fourth Quarter 2023"},{"label":"Revenue","value":"$21.2 million"},{"label":"Net income","value":"net income of $0.1 million"},{"label":"EPS","value":"$0.00 earnings per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"f23a4db9159eda1e1c34f074edfba341bf500d14","claim":"Niagen Bioscience, Inc. reported Fiscal Year 2023 results: revenue $83.6 million, net income net loss of only $4.9 million, EPS $0.07 loss per share.","evidence_excerpt":"Full year net sales of $83.6 million, up 16% from the prior year, gross margin of 60.8%, net loss of only $4.9 million, positive Adjusted EBITDA of $1.9 million and positive operating cash flows.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1386570/000162828024009383/0001628280-24-009383-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Fiscal Year 2023"},{"label":"Revenue","value":"$83.6 million"},{"label":"Net income","value":"net loss of only $4.9 million"},{"label":"EPS","value":"$0.07 loss per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}